ArticleInternational journal of chronic obstructive pulmonary disease2025
Treatment Patterns and Triple Therapy Utilization in Chinese Patients with Chronic Obstructive Pulmonary Disease: An Analysis of Real-World Data from the Yinzhou Database.
Article in International journal of chronic obstructive pulmonary disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Profiles and Disease Burden of Patients with COPD Initiating Triple Therapy in China.International journal of chronic obstructive pulmonary disease · 2026Observational
- Disease Burden and Unmet Needs in Chinese Patients with Symptomatic and Exacerbating COPD While on Triple Inhaled Therapy: A Cross-Sectional Real-World Study.International journal of chronic obstructive pulmonary disease · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Triple therapy of chronic obstructive pulmonary disease (COPD), consisting of inhaled corticosteroid (ICS), long-acting β2-agonist (LABA) and long-acting muscarinic antagonist (LAMA) has shown benefits in patients with COPD. However, little is known about the use of triple therapy in Chinese patients. This study aims to describe the treatment patterns and the utilization of triple therapy in COPD patients based on real-world data from China. Patients and Methods: This retrospective study included patients with COPD from the Yinzhou database. Patients aged ≥ 40 years with a diagnosis of COPD were included. Different combinations of ICS, LAMA and LABA prescribed during follow-up were categorized as single, dual, or triple therapies. Descriptive analysis was performed to depict the treatment patterns of each therapy. Results: A total of 7888 patients were prescribed at least one COPD therapy during the follow-up. Among them, 29.1% were prescribed triple therapy (ICS+LABA+LAMA) with a median (IQR) treatment duration of 3.27 (7.17) months. The majority (68.6%) of patients were prescribed dual therapy with ICS+LABA, while 27.3% and 23.3% of patients were prescribed single therapy with ICS or LAMA, respectively. Regarding treatment sequences during follow-up, 30.1% of patients received dual therapy with ICS+LABA, followed by 11.4% receiving only triple therapy and 10.4% receiving single therapy with ICS alone. Conclusion: Our study assessed treatment patterns and triple therapy utilization among patients with COPD in China. The majority of patients were treated with ICS+LABA dual therapy. Triple therapy was also widely used, with most patients transitioning from other treatment modalities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.